期刊文献+

钙蛋白酶10基因Indel-19与2型糖尿病及胰岛素抵抗的关系 被引量:4

Correlations between calpain 10 gene and insulin resistance in type2 diabetes.
下载PDF
导出
摘要 目的研究钙蛋白酶10基因Indel-19与2型糖尿病及胰岛素抵抗的关系。方法选取120例2型糖尿病患者和92例非糖尿病健康对照者,用聚合酶链反应法(PCR)扩增目的基因,琼脂糖电泳,检测所有受试者的Indel-19基因型,采用生化技术测定空腹血糖、血脂以及空腹胰岛素水平(FINS),用胰岛素抵抗指数HOMA-IR评价胰岛素抵抗。结果2型糖尿病组较对照组有较高的TG、TC、LDL、BMI和IR水平(P<0.05),两组钙蛋白酶10基因Indel-19基因型22的频率分别为54.2%和44.6%,差异无统计学意义;在2型糖尿病人群中Indel-19基因型22的个体较基因型11和12的个体有较高的FINS、IR水平和较低的高密度脂蛋白(HDL)水平(P<0.01,P<0.05)。结论钙蛋白酶10基因Indel-19的基因型22与江苏地区2型糖尿病人群的胰岛素抵抗相关。 Objective To study the correlations between calpain 10 gene polymorphism and insulin resistance in type 2 diabetes.Methods 120 type 2 diabetes patients and 92 normal control subjects were investigated;polymerase chain reaction(PCR) was used to determine the genotypes of site Indel-19 in calpain 10 gene.Results Higher TG、TC、LDL、BMI and IR were found in type 2 diabetes patients(P〈0.05);No difference was found in the ditribution of genotype of site Indel-19 between the two groups;In the type 2 diabetes group,higher FINS、IR and lower HDL were found in the individuals with genotype 22 than those of individuals with genotype 11 and 12(P〈0.01,P〈0.05).Conclusion The study suggested that Indel-19 of Calpain 10 gene correlated to insulin resistance in type 2 diabetes.
出处 《四川医学》 CAS 2008年第7期832-834,共3页 Sichuan Medical Journal
基金 镇江市科技计划项目(SH20050049)
关键词 钙蛋白酶10基因 2型糖尿病 胰岛素抵抗 calpain 10 gene type 2 diabetes insulin resistance
  • 相关文献

参考文献8

  • 1Hofikawa Y, Naohisa Oda, Cox NJ, et al. Genetic variation in the gene encoding Caplain-10 is associated with type 2 diabetes mellitus[J]. Nature Genetics,2000,26(2) :163 - 175.
  • 2徐成斌.他汀类药物治疗血脂异常的作用、地位和进展[J].中华内分泌代谢杂志,2000,16(6):385-388. 被引量:12
  • 3Turner MD, Cassell PG, Hitman GA. Calpain-10: from genome search to function[J]. Diabetes Metab Res Rev,2005,21(6) :504 - 514.
  • 4Cox NJ. Calpain 10 and genetics of type 2 diabetes[J]. Curr Diab Rep, 2002,2(2) : 186- 190.
  • 5Turner MD, Fulcher FK; Jones CV, et el. Calpain facilitates aetin reorganlzation during glucose-stimulated insulin secretion[J]. Bioehem Biophys Res Commun, 2007,352 : 650 - 655.
  • 6Marshall C, Hitman GA, Partridge CJ, etal. Evidence that an isoform of ealpain-10 is a regulator of exocytosis in pancreatic btea-eells[ J]. Mol Endocrinol,2005,19 : 213 - 224.
  • 7Shima Y, Nakanishi K, Odawara M, et al. Association of the SNP-19 genotype 22 in the caplain-10 gene with elevated body mass index and hemoglobin Ale levels in Japanese[ J]. Clin Chim Acta, 2003,336 ( 1 - 2) :89- 96.
  • 8Hoffstedt J, Naslund E, Amer P. Calpain-10 gene polymorphism is associated with reduced beta( 3 )-adrenoceptor function in human fat cells[ J ]. J CLin Endocrinol Metab, 2002,87 (7) : 3362 - 3367.

二级参考文献10

  • 1.SummaryofthesecondreportoftheNationalCholesterolEducationProgram (NCEP)ExpertPanelondetection ,evaluationandtreat mentofhighbloodcholesterolinadults (AdultTreatmentPanel11)[].The Journal of The American Medical Association.1993
  • 2AmericanDiabetesAssociation.Managementofdyslipidemiainadultswithdiabetdes (positionstatement)[].Diabetes Care.1998
  • 3BischoffH,AngerbauerR,BenderJ,etal.Cerivastatin :pharma cologyofanovelsyntheticandhighlyactiveHMA CoAreductaseinhibitor[].Atherosclerosis.1997
  • 4Farmer JA,Gotto AM.Dyslipidemia and other risk factors for coronary artery disease.In Braunwald E ed: Heart disease: a textbook of cardiovasular medicine, 5th Ed. 1997, W. B. Saunders Co[].Philadelphia Medicine.
  • 5Bischoff H. Angerbauer R,Bender J,et al.Cerivastatin: pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor[].Atherosclerosis.1997
  • 6Bakker-Arkema RG,Davidson MH,Goldstern RJ,et al.Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[].The Journal of The American Medical Association.1996
  • 7Bocuzzi SJ,Bocanegra TS,Walker JF,et al.Long-tem safety and efficacy profile of simvastatin[].The American Journal of Cardiology.1991
  • 8Du jovne CA,Chremos AN,Pool JL,et al.An expandedc lin ical evaluation of lovastatin(EXCEL)study resu lts.Ⅳadd itional perspectives on the tolerab ility of lovastatin[].The American Journal of The Medical Sciences.1991
  • 9Hsu I,Spinler SA,Johnson NE.Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia[].Annals of Pharmacotherapy.1995
  • 10Pedersen TR.The scandinavian simvastatin survival study group[].Randomized trial of cholesterol lowering in patients with coronary heart disease: the scandinavian simvastatin survival study(S) Lancet.1994

共引文献11

同被引文献75

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部